A new apoptotic pathway for the complement factor B-derived fragment Bb

✍ Scribed by Masaya Uwai; Yasuhito Terui; Yuji Mishima; Hiroshi Tomizuka; Masayuki Ikeda; Takehito Itoh; Masaki Mori; Masuzu Ueda; Rie Inoue; Muneo Yamada; Hirotoshi Hayasawa; Takahiko Horiuchi; Yoshiyuki Niho; Mitsuru Matsumoto; Yukihito Ishizaka; Kazuma Ikeda; Keiya Ozawa; Kiyohiko Hatake

• Book ID: 101336343
• Publisher: John Wiley and Sons
• Year: 2000
• Tongue: English
• Weight: 313 KB
• Volume: 185
• Category: Article
• ISSN: 0021-9541
• DOI: 10.1002/1097-4652(200011)185:2<280::aid-jcp13>3.0.co;2-l

✦ Synopsis

Apoptosis is involved in both the cellular and humoral immune system destroying tumors. An apoptosis-inducing factor from HL-60 myeloid leukemia cells was obtained, purified, and sequenced. The protein found has been identified as a human complement factor B-derived fragment Bb, although it is known that factor B is able to induce apoptosis in several leukemia cell lines. Monoclonal antibodies against fragment Ba and Bb inhibited the apoptotic activity of factor B. When the purified fragment Bb was used for apoptosis induction, only the anti-Bb antibody inhibited Bb-induced apoptosis, and not the anti-Ba antibody. The apoptosis-inducing activity was found to be enhanced under conditions facilitating the formation of Bb. Blocking TNF/TNFR or FasL/Fas interactions did not interfere with the factor B-induced apoptosis. CD11c (iC3bR) acts as the main subunit of a heterodimer binding to fragment Bb in the apoptosis pathway, and the factor B-derived fragment Bb was found to possess the previously unknown function of inducing apoptosis in leukemic cells through a suicide mechanism of myeloid lineage cells during the differentiation stage.